6216results about "Senses disorder" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The invention discloses a cationic lipid compound, a lipid carrier containing the same and application, and belongs to the technical field of gene therapy. The cationic lipid compound disclosed by the invention has a structure as shown in a formula I, or an isomer, a pharmaceutically acceptable salt and a prodrug thereof. The lipid nanoparticles have the advantages of stable nanostructure, uniform size distribution, good biological biocompatibility, high in-vivo and in-vitro mRNA delivery efficiency, selective organ targeting and the like. The cationic lipid reaction operation is simple, the raw materials are cheap and easy to obtain, and the cationic lipid has high safety, is beneficial to industrial production and quality control, and has a good application prospect.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.

An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention relates to a near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system and a preparation method and application thereof, a mesoporous silicon coated up-conversion nano-carrier and an efficient photosensitizer are compounded to form a photo-response core unit, and then the photo-response core unit is intelligently integrated with photo-curing hydrogel to form the near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system. The general problem of aggregation and quenching of photosensitive molecules is relieved by utilizing the unique space confinement effect of the mesoporous structure, the ICG photo-thermal efficiency and photodynamic performance are enhanced, under precise excitation of a near-infrared light source, the system can activate a photo-crosslinking reaction through an up-conversion luminescence process, in-situ conversion from a liquid eye drop preparation to a stable gel state is achieved, and the stability of the eye drop preparation is improved. A lasting drug reservoir is formed on the surface of the cornea; synchronously excited photodynamic and photo-thermal dual-mode treatment generates a remarkable synergistic antibacterial effect, and shows an excellent removal capability on pathogens including highly drug-resistant bacteria; meanwhile, an ideal microenvironment is created for tissue repair through high biocompatibility and a stable mechanical matrix, and integrity recovery of cornea structures and functions is promoted.

The present invention relates to compounds of formula (I), their synthesis and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders. [Formula 1] TIFF2023523300000191.tif51156

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

Disclosed are compounds, pharmaceutical compositions and uses thereof as complement factor D inhibitors, specifically a compound represented by formula (I), its tautomers, its stereoisomers, its prodrugs, or any one of the foregoing pharmaceutically acceptable salts, or any one of the foregoing solvates, wherein the compound has excellent inhibitory activity against complement factor D and has excellent pharmacokinetic and pharmacodynamic activity. JPEG2024533782000131.jpg47170

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention relates to the technical field of medicines, in particular to application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating myopia. The invention provides application of alpha-ketoglutaric acid or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating myopia, and the alpha-ketoglutaric acid is taken as an important intermediate metabolite of tricarboxylic acid cycle in mitochondrial aerobic respiration and has oral safety; researches show that alpha-ketoglutaric acid can inhibit myopia progress and ocular axis elongation by improving sclera fibroblast phenotype transformation and extracellular matrix remodeling, and a new idea is provided for preparation of myopia intervention drugs.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating meniere disease membrane hydrolost and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: rhizoma alismatis, rhizoma atractylodis macrocephalae, poria cocos, gastrodia elata, ginger processed pinellia, pericarpium citri reticulatae and fresh ginger. The traditional Chinese medicine composition disclosed by the invention is small in dosage and special in effect, and dialectical compatibility is performed according to the phlegm-dampness theory of traditional Chinese medicine, combined with the pathological basis of the meniere disease and based on the treatment rules of transforming fluid retention, inducing diuresis, tonifying spleen and calming liver, so that the aim of treating both symptoms and root causes is achieved. Animal experiments prove that the traditional Chinese medicine composition can obviously relieve the cochlear hydrops degree of a rat with membranous hydrolost.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The present invention belongs to the field of biotechnology. Disclosed is a dosage composition of a complement factor B inhibitor. Specifically, the present invention provides a pharmaceutical composition comprising a compound represented by formula I, an isomer thereof, or a pharmaceutically acceptable salt thereof in a unit dosage form, wherein the mass of the compound or the pharmaceutically acceptable salt thereof is 5-1500 mg based on the free base.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention discloses a temperature-sensitive hydrogel loaded with mesenchymal stem cell exosome as well as a preparation method and application of the temperature-sensitive hydrogel, and belongs to the technical field of biological medicines. The method comprises the following steps: (1) adding poloxamer 407 into a pre-cooled dispersion medium to enable the final mass concentration to be 20-30%, and oscillating and dissolving at 4 DEG C overnight to obtain poloxamer hydrogel; (2) collecting a mesenchymal stem cell culture supernatant, and then centrifuging, wherein the centrifuging condition is 200 * g * 15 minutes to 2000 * g * 20 minutes to 12000 * g * 20 minutes; filtering the supernatant, concentrating by using an ultrafiltration tube, further performing ultracentrifugation on the concentrated solution, re-suspending the precipitate by using DPBS, centrifuging again, and re-suspending the finally obtained exosome precipitate by using DPBS to obtain an exosome suspension; the ultracentrifugation condition is as follows; and (3) taking the poloxamer hydrogel prepared in the step (1), adding the exosome suspension obtained in the step (2) under an ice-water bath condition, and uniformly mixing to obtain the poloxamer temperature-sensitive hydrogel.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.